Company
4D Molecular Therapeutics Inc.
FDMTBiotechnology
Business description
4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company founded in 2018 that develops innovative DNA-based treatments for cancer and genetic disorders. Its pipeline features lead candidate FDMT-101 alongside additional programs such as FDMT-102 and FDMT-103, supported by a proprietary delivery platform. Under the leadership of CEO Dr. Michael Hauser and CFO Amanda Clarke, the company has raised over $50 million through strategic collaborations and milestone-based agreements. With several Phase I/II trials on the horizon, 4D Molecular Therapeutics is positioned as a promising emerging competitor in the biotech sphere.
$85M
Revenue (LTM)
—
Acquisitions
-187.2%
Operating margin
—
Latest call
01 Explore
Everything on 4D Molecular Therapeutics Inc.
Financials
Revenue (FY2025)
YoY growth
Operating margin
Direction
Gross margin
Net margin
Leadership & board
Competitors
Named competitors
AbbVie Inc.REGENXBIO Inc.Adverum Biotechnologies Inc.Eli Lilly and CompanyEyePoint Inc.Ocular Therapeutix Inc.Kodiak Sciences Inc.Merck & Company Inc.Regeneron Pharmaceuticals Inc.RocheApellis Pharmaceuticals Inc.Astellas Pharma Inc.Annexon Biosciences, Inc.Belite Bio, Inc.Johnson & JohnsonAlnylam Pharmaceuticals, Inc.SanofiStealth BioTherapeutics Inc.